Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
Rhea-AI Summary
Soleno Therapeutics (NASDAQ: SLNO) will report fourth quarter and full-year 2025 financial results after market close on Wednesday, February 25, 2026.
The company will host a conference call and webcast at 4:30 PM ET to discuss results and operational highlights. A live dial-in, international line, conference ID 55257, and a webcast link will be provided. A replay will be available for 30 days on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SLNO declined 1.11%, reflecting a mild negative market reaction. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $23M from the company's valuation, bringing the market cap to $2.05B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SLNO was down 0.93% while key biotech peers were mixed: IMVT -2.98%, MLYS -2.48%, SRRK -0.16%, VKTX -1.2%, and RARE +3.02%, indicating stock-specific trading rather than a clear sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Conference participation | Neutral | -2.5% | Participation in three upcoming investor conferences with webcast access. |
| Jan 12 | Prelim 2025 results | Positive | -3.4% | Preliminary 2025 net revenue, profitability, and cash flow tied to VYKAT XR launch. |
| Jan 05 | Clinical publication | Positive | -4.1% | Positive pivotal VYKAT XR randomized withdrawal study results in PWS patients. |
| Dec 03 | Board member death | Negative | +3.9% | Announcement of audit committee chair’s passing and expected leadership transition. |
| Nov 24 | Conference appearance | Neutral | +1.8% | CEO fireside chat at Piper Sandler healthcare conference with webcast. |
Recent fundamentally positive updates have often seen negative next-day moves, suggesting a pattern of divergence between news tone and price reaction.
Over the last few months, SLNO has reported pivotal VYKAT XR study publication, strong preliminary 2025 revenue and profitability tied to the U.S. launch, and multiple conference participations. Despite generally constructive business updates, the stock often moved lower the next day, while a negative management event on Dec 3, 2025 coincided with a positive reaction. Today’s earnings-date announcement fits into a period of active news flow ahead of final audited 2025 results.
Market Pulse Summary
This announcement sets the timetable for Soleno’s fourth quarter and full-year 2025 results, with a conference call on February 25, 2026 at 4:30 PM ET. It follows earlier preliminary revenue and profitability disclosures and key clinical publications for VYKAT XR. Investors may focus on how final audited numbers compare with preliminary figures, management’s commercial outlook, and any updated operational milestones discussed on the call and webcast replay.
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Wednesday, February 25, 2026 |
| Time: | 4:30 PM Eastern Time |
| United States: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Conference ID: | 55257 |
| Webcast: | Link |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKATTM XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When will Soleno Therapeutics (SLNO) release its Q4 and full-year 2025 results?
What time and access details are available for the SLNO earnings call on February 25, 2026?
Will Soleno Therapeutics (SLNO) provide a webcast and replay for the February 25, 2026 call?
What topics will Soleno Therapeutics (SLNO) cover in the February 25, 2026 conference call?
How can international investors join the Soleno Therapeutics (SLNO) Feb 25, 2026 call?
